Montelukast Drug Review: PTCB Exam Study Notes

Montelukast Overview for Pharmacy Technicians

Montelukast is a widely prescribed medication for asthma and allergic rhinitis, and its recent FDA black box warning makes it an especially important drug for the PTCB certification exam. Understanding its classification, uses, and safety concerns is essential for pharmacy technicians.

Brand Name and Classification

Montelukast is sold under the brand name Singulair. It belongs to the leukotriene receptor antagonist (LTRA) class. Zafirlukast (Accolate) is another drug in this class. These medications are sometimes called leukotriene modifiers.

Mechanism of Action

Montelukast blocks leukotriene D4 receptors in the airways. Leukotrienes are inflammatory mediators released during allergic and asthmatic responses that cause bronchoconstriction, mucus secretion, and airway edema. By blocking their receptors, montelukast reduces airway inflammation and bronchoconstriction.

Common Indications

Asthma prevention: Maintenance treatment for chronic asthma (not for acute attacks)
Allergic rhinitis: Seasonal and perennial allergy symptoms
Exercise-induced bronchoconstriction: Prevention when taken at least 2 hours before exercise

Dosing by Age Group

Montelukast dosing varies by age, which is commonly tested:

Adults and adolescents (15+ years): 10 mg tablet once daily in the evening
Children 6-14 years: 5 mg chewable tablet once daily in the evening
Children 2-5 years: 4 mg chewable tablet or granules once daily in the evening
Children 6-23 months (granules only): 4 mg granules once daily in the evening

Montelukast should be taken in the evening for asthma and can be taken at any time for allergic rhinitis.

FDA Black Box Warning

In 2020, the FDA added a black box warning to montelukast for serious neuropsychiatric events including:

Agitation and aggressive behavior
Depression and suicidal thoughts
Hallucinations and disorientation
Insomnia and sleep disturbances
Attention and memory problems

The FDA now recommends that montelukast be reserved for patients who have not responded adequately to other therapies or who cannot tolerate alternative treatments. This black box warning is high-yield for the PTCB exam.

Side Effects

Headache: Most commonly reported
Upper respiratory infection: Reported in clinical trials
Abdominal pain: Occasional GI discomfort
Neuropsychiatric effects: As described in the black box warning

PTCB Exam Tips

Key facts: montelukast is brand Singulair, it is a leukotriene receptor antagonist, it is for prevention not rescue, taken in the evening, dosed by age, and carries a black box warning for neuropsychiatric events.

Review respiratory medications at PTCBprep flashcards and practice at our mini exams.